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Abstract Phospholipase C$ (PLC-& is a phospholipid-con- 
verting enzyme which, upon receptor stimulation, is activated 
within membrane-bound signalllng complexes. In contrast to the 
highly ubiquitous PLCy’, PLCJ is expressed predominantly in 
B-lymphocytes. Associated with antigen-coupling receptors it is 
activated by tyrosine phosphorylation after the triggering of B- 
cell surface immunoglobulin. We have cloned and sequenced the 
human PLCJ promoter. Primer extension analysis reveals the 
existence of a major transcriptional start site. The TATA-less 
promoter contains G+C-rich stretches with a cluster of 
contiguous SPl consensus sites, an NFl, and an AP2 site 
between bp -220 to -70. A construct containing the region from 
-189 to +78 confers full promoter activity, as shown by fusion to 
a luciferase reporter gene construct. The distal part of the 
promoter between bp -662 to -293 containing an SRE, EBF and 
CACCC box contributed negatively to promoter activity in the 
B-cell line Raji but not in three adherent cell lines. In Raji cells, 
PLCJ mRNA is expressed at low levels with a half life greater 
than 4 h. After treatment with serum, TPA, retinoic acid, or with 
5azacytidine increased levels of PLC? mRNA were induced in 
B-cells. 
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1. Introduction 
PLCY is a tissue-specific phospholipase, catalyzing the 
cleavage of phosphatidylinositole bisphosphate into the sec- 
ond messengers inositol 1,4,5_trisphosphate and diacylglycerol 
[l]. As these second messengers act as primary signal trans- 
ducers for calcium mobilization as well as activators for pro- 
tein kinase C, phospholipases of type C are essential compo- 
nents of many mitogen-induced signal cascades, especially of 
those involving receptor-associated tyrosine kinase activity [2]. 
Common to both isoforms of the PLCy family are regions of 
homology to the src tyrosine kinase non-catalytic domain, 
SH2 and SH3 [3]. Ligand-induced receptor activation can re- 
sult in tyrosine phosphorylation of a receptor or its associated 
molecules, thereby generating binding sites for the PLCr SH2 
domains. Binding through the SH2 domains leads to PLCr 
activation through subsequent tyrosine phosphorylation. In 
contrast to the ubiquity of its closely homologous isozyme, 
PLCyr, PLCY expression is limited to the blood-drained tis- 
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sues of lung and spleen and to cells of the hematopoietic 
lineage, predominantly B-cells and monocytes [4-61. The pro- 
tein is co-immunoprecipitated with components of the B-cell 
receptor [7] where it is likely to interact with associated tyr- 
osine kinases through its SH2 and SH3 domains [8,9]. 
Further, it is rapidly hyperphosphorylated after stimulation 
of CD40, a receptor of the tumor necrosis factor gene family, 
expressed and activated during the clonal expansion of B-lym- 
phocytes [lo]. It is therefore thought to be implicated in the 
signal transduction of antigen-triggered B-cell responses, as 
well as in B-cell growth and differentiation [1 11. Recently, 
the genetic locus of PLCY has been mapped to the long 
arm of human chromosome 16 in band q24.1 [ 121. 
To investigate the transcriptional regulation of the PLw 
gene, we cloned and sequenced 1.5 kb of the PLCY promoter 
region. In addition, we have identified the transcriptional start 
site, possible regulatory elements and characterized the pro- 
moter by deletional analysis in transfected B-cells and fibro- 
blasts. Furthermore, the transcriptional activation of the 
PLC$ gene in various B-cell lines was studied. 
2. Materials and methods 
2.1. Cloning and DNA sequencing 
A human genomic EMBL 3A-h-library derived from the Burkitt’s 
lymphoma line Ly66 (a generous gift of M. Lipp, Max Delbrtick 
Zentrum, Berlin Buch) was screened by plaque hybridization. h- 
DNA preparation and screening were carried out using Qiagen re- 
agents according to standard protocols [13]. Phage clones were 
screened using a 2.2 kb probe derived from human PLCY cDNA 
[14] using the ECL direct nucleic acid labelling protocol from Amer- 
sham. Inserts were removed with San, cloned into Bluescript KS+ 
(Stratagene), and analysed by Southern blotting [13] using a 5’-fluo- 
rescein 1 I-dUTP-labelled oligonucleotide A (S’-GACTCGGGT- 
CACTCAGCGCC-3’) derived from nucleotide 7 to 26 of the pub- 
lished PLC? cDNA [14] as the probe and using the ECL protocol as 
recommended by the manufacturer (Amersham). The DNA sequenc- 
ing reaction carried out according to Sanger et al. [15], using Y-fluo- 
rescein-labelled 17 mer-oligonucleotide primers derived from PLCY 
cDNA or promoter sequences. Gel electrophoresis and sequence anal- 
ysis were performed on an automated laser fluorescence (ALF) se- 
quencer (Pharmacia). 
2.2. Primer extension 
The reaction was done essentially as described by M&night and 
Kingsbury [16]. Using a Pharmacia gene assembler, a fluoresc&-end- 
labelled oligonucleotide B (5’-CGGGAGAAATCAGGAAGCTG-3’) 
was synthesized complementary to nucleotide 103-122 of the PLC+ 
cDNA and hybridized overnight at 30°C with 25 pg of RNA isolated 
from Epstein-Barr virus transformed lymphoblastoid B-cells (a gift 
from I.-Melchers, University of Freiburg).-Reverse transcription was 
allowed to proceed for 2 h at 37°C using M-MuLV reverse transcrip- 
tase (Pharmacia), and the reaction products were then separated in a 
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6% polyacrylamide gel containing 8 M urea [13]. The reaction prod- 
ucts were analyzed using an ALF sequencer. 
2.3. Expression vectors, cell culture and promoter assays 
PLCY promoter fragments were ligated 5’ to the luciferase reporter 
vector PAH1409 [17] either blunt end or after a filling reaction into 
the filled-in XhoI or BamHI sites of the vector as depicted in Fig. 3A. 
NIH3T3, 293, and Ltk- cells were grown in DMEM with high glu- 
cose (4.5 g/l), sodium bicarbonate (3.7 g/l) and 10% calf serum (Life 
Technologies). The cell lines BJA-B and Raji, as well as EBV trans- 
formed primary lymphoblastoid cells, were cultured in RPM1 1640 
plus fetal calf serum (FCS) as indicated. All media were supplemented 
with penicillin (100 U/ml) and streptomycin (100 l&ml; Life Tech- 
nologies). NIH3T3, 293, and Ltk- cells were transiently transfected by 
the calcium phosphate method [18], each with 2 pg reporter plasmid 
DNA and lpg of the B-galactosidase expression plasmid pRSV-1acZII 
(Pharmacia). The cell lines BJA-B and Raji were transfected by elec- 
troporation at 250 V, 960 pF using 25 ug of reporter DNA for 
each transfection and 1 ug of pRSV-1acZII. Cells were harvested 
4448 h later and luciferase assays performed as described [19]. Lu- 
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ciferase activity was normalized for transfection efficiency as deter- 
mined by S-galactosidase activity [19]. For each reporter plasmid 
and cell line, a minimum of two independent transfections was per- 
formed. 
2.4. RNA analysis 
1 x lo7 cells were either untreated left or stimulated with TPA (100 
@ml), retinoic acid (10 pM) or actinomycin D (5 pg/ml) for an 
indicated time. The cells were then lysed in 4 M guanidinium isothio- 
cyanate plus 0.5% lauroylsarcosin, 25 mM sodium citrate and 0.1 M 
2-mercaptoethanol, pH 7.0. Total RNA was isolated by centrifugation 
through a cushion of 5.7 M CsCl [20]. RNAs (20 @sample) were 
separated in either 0.8% or 1% agarose-6% formaldehyde gels and 
blotted onto Hybond-N nylon membranes (Amersham) using 20X 
SSC. The RNA blots were hybridized to random prime 32P-labelled 
probes derived from the PLCY cDNA [14], and then washed accord- 
ing to standard conditions [13]. The relative abundance of RNA per 
lane was checked by comparison of the ethidium bromide staining of 
the ribosomal RNA bands and by hybridizization of RNAs with a 
probe of the housekeeping gene, glyceraldehyde-3-phosphate dehydro- 
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Fig. 1. Nucleotide sequence of the 5’ region of the PL@ gene. Potential transcription factor binding sites and restriction sites are indicated 
(underlined). The arrow at position +l indicates the main transcriptional start site determined by primer extension analysis. The sequence re- 
ported from this paper is available from the EMBL data library with the accession no. Z 22522. 
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genase (GAPDH) [21]. Blots were autoradiographed using Kodak X- 
OMAT AR5 films, exposed at -70°C. 
3. Results 
3.1. Cloning of the human PLCY promoter 
A cDNA of PLCY from transformed human lymphocytes 
had been isolated previously [14]. For cloning of the PLCY 
promoter, DNA of a h-EMBL-3A-library derived from the 
human Burkitis lymphoma cell line Ly66 was screened with 
a 2.2 kb PLCF cDNA probe [14]. Fifteen h-phage-clones were 
isolated. 
These clones were cut with SalI, EcoRI or BarnHI and 
monitored by Southern blot analysis using a 20mer oligonu- 
cleotide homologous to nucleotides +7 to +26 of the PLCY 
cDNA [14], resulting in two clones containing a positive 5.5 
kb BarnHI-fragment (data not shown). The 5.5 kb BarnHI 
fragment and subfragments thereof were subcloned into Blue- 
script KS+ (Stratagene). The first exon (103 bp, see primer 
extension experiment), part of the first intron (124 bp) and the 
upstream region of the PLW gene (1239 bp) were sequenced. 
The major transcriptional start site was designated as +l 
(Fig. 1). Several notable features were detected in the sequence 
5’ of exon 1 within the putative promoter region. The prox- 
imal, GC-rich part of the promoter lacks a TATA box, but 
contains a cluster of five Spl motifs (positions -73, -100, -110, 
-134, -209, relative to the major transcriptional start site). 
Four GC-factor consensus sites [22] partially overlap the 
Spl sites at positions -98, -108, -112 and -207 (consensus 
GCGGGGC). In addition, a Myc/Max consensus site is lo- 
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cated at position -55, AP-2 sites at positions -174 and -689, 
and a serum response element at position -567. For other, 
potential transcription factor binding sites, including those 
located at positions 3’ of the transcriptional start site (see 
Fig. 1). 
3.2. Site of transcriptional initiation 
The PLCY transcriptional start site was mapped by primer 
extension using a fluorescent-tag labelled 19mer oligonucleo- 
tide derived from nucleotides 97-l 15 of the PLCY cDNA 
[14]. Twenty-five pg RNA of a lymphoblastoid cell line were 
used for the reaction. Gel electrophoresis analysis was per- 
formed on an automated laser fluorescence sequencer (Phar- 
macia). As an internal marker, a sequence reaction for a 
PKCC gene was co-electrophoresed. A major extension prod- 
uct of 119 bases was detected (Fig. 2). Primer extension with 
RNA from the T-cell-line Jurkat confirmed this extension 
product (data not shown). The band of 119 bases corresponds 
to position +l in Fig. 1 and maps 4 bp upstream of the 
previously published PLCY cDNA [14]. 
3.3. Deletional analysis of the PLC?$ promoter 
For a functional identification of the PLCY promoter, and 
in order to define the regions required for promoter activity, 
we cloned a series of progressively deleted DNA fragments of 
the putative promoter directly upstream of the firefly lucifer- 
ase reporter gene (ZUC) (Fig. 3A). The resulting plasmids were 
transiently expressed in the murine fibroblast cell lines NIH 
3T3, Ltk-, and the human embryonal kidney cell line 293. 
None of these cell lines express detectable amounts of RNA 
1 
110 n * Y R Y 
Fig. 2. Automated primer extension using fluorecein-labelled oligonucleotides. A: Sequenced PKC-zeta (without lane 4 for thymine) as a size 
marker sequence. B: Extended product at position 119 using oligonucleotide B as primer, derived from nucleotides 103-121 of the PLCg 
cDNA. The size of extension products increases from left to right. For details see Sections 2 and 3. 
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Fig. 3. Luciferase promoter-reporter assays using promoter fragments of the human PLW gene. A: Promoter deletion constructs, generated as 
described in Section 2. B: Luciferase activity of the corresponding constructs after transfection into NIH3T3, Ltk-, 293, Raji or BJA-B cells. 
Data were obtained as described in Sections 2 and 3 and are expressed in relative light units (RLE). The high differences of RLE levels be- 
tween different cell lines mainly reflect the cell-specific transfection efficiency of a respective cell line as determined by transfection experiments 
with a control expression plasmid for luciferase under the control of a CMV early promoter (data not shown). 
of the endogenous PLC$ gene. Two human B-lymphoma cell 
lines which both express low levels of PLCg RNA, Raji and 
BJA-B, were similarly transfected. 
The pattern of activities determined for all constructs was 
similar for NIH 3T3, Ltk-, 293, and BJA-B cells but mark- 
edly different from the pattern detected for Raji cells. The two 
longest constructs, L/P and L/P/S, produced relatively strong 
signals except in Raji cells. Further 5’ deletion of the con- 
structs, LIP/E and L/P/St, led to a 2- to lo-fold increase of 
activity in Raji cells, whereas only a slight or no increase was 
detected for the other cell lines. This identified a negative 
element in the distal part of the PLCY promoter between 
-895 bp and -198 bp which operates in Raji cells but not in, 
or only inefficiently in, the other tested cell lines. Deletion of 
the StuZlAscZ fragment, corresponding to the region from -198 
to -120, led to reduction of luc-activity. The decline was most 
pronouced in Raji cells, although barely evident in 293 cells. 
The further deletion of the AscNSucZZ fragment corresponding 
to the region from -120 to -42, abolished luc-activity in Raji 
cells, but had only a minor effect in BJA-B cells. This result 
suggests that the PLCY promoter harbours at least two pos- 
itive elements in the region -198 bp to -42 bp, and negative 
elements upstream of postion -198 bp. 
To uncover the mechanisms of stimulus-dependent promo- 
ter regulation, we transfected NIH3T3, 293 and BJA-B cells 
with the promoter-luciferase constructs L/J?, L/P/E and L/P/ 
18 
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Fig. 4. Stability and expression of RNA in lymphoid cells. A: PLCY RNA stability in Raji. Northern blots were made with RNA from Raji 
cells treated with actinomycin D for the indicated hours as described in Sections 2 and 3. The upper panel shows the time course with PLC? 
RNA, the lower panel that of c-myc. B: Stimulus-dependent PLCj! expression in BJA-B-lymphoma cells by TPA and retinoic acid (RA). Cells 
were kept under low serum conditions as described in Section 2 and stimulated for an indicated time. C: RNA induction in Raji cells by the 
DNA-demethylating agent 5 aza-cytidine. Raji were either untreated (0) or treated with 1 pM of Sazacytidine for 48 h (48). 
St. The transfected cells were then stimulated with TPA, 8- 
bromo-CAMP [23,24], or dexamethasone [25]. All three com- 
pounds elicited minor or no detectable effects compared to the 
untreated control (data not shown). 
3.4. High stability of PLC$ mRNA in B-cell-line Raji 
The transcriptional block by actinomycin D has been 
shown to be a reliable tool for measuring RNA turnover in 
various cellular contexts [26]. RNA was isolated from Raji 
cells at different times after addition of the drug and studied 
by Northern analysis. RNA was hybridized either to a 32P- 
labelled PLCY cDNA or, for control, to a labelled c-myc 
cDNA (Fig. 4A). The rapid decrease of c-myc RNA with a 
half life of less than 0.5 h upon addition of actinomycin D 
confirmed earlier reports [26,27]. In contrast, the PLCg 
RNA, even though expressed at low levels, was very stable 
and showed no decrease of steady-state levels during the time 
course of the experiment. 
3.5. Activation of PL@ in B-cell lines 
Through cloning and deletion analysis, various putative 
promoter elements and regions have been characterized which 
may regulate the expression of PLCY at its endogenous locus. 
We investigated the regulation of PLCY expression by North- 
ern analysis using RNA from stimulated cell cultures of the 
lymphoma cell line BJA-B. BJA-B cells were stimulated with 
TPA or retinoic acid (Fig. 4B), substances associated with the 
induction of various B-cell responses. Treatment of BJA-B 
cells led to a marked increase of PLCY RNA after 3 h. 
RNA levels remained high for as long as 24 h. Retinoic 
acid treatment of BJA-B cells did not affect steady-state 
PLCY RNA levels within the first 3 h of treatment, but led 
to a strong induction after 24 h. The steady-state RNA levels 
of the GAPDH gene were not affected by TPA or retinoic 
acid. We have also observed a detectable increase in PLCjl 
protein levels upon TPA and retinoic acid stimulation, 
although this was much more moderate compared to the in- 
crease in RNA (data not shown). 
To investigate methylation as a possible mechanism of tis- 
sue-specific gene activation, Raji cells were treated for 48 h 
with 1 pM of the demethylating agent 5-azacytidine, and 
RNA isolated. Northern blots hybridized with a PLCf-spe- 
cific probe reveal a sizable increase of PLCY expression with 
5-azacytidine treated Raji cells (Fig. 4C). In NIH3T3 cells, 
however, which are negative for PLCY, 5-azacytidine did 
not induce any detectable in PLC? RNA levels (data not 
shown). Thus demethylation of regulatory sequences of the 
PLW gene or demethylation of a locus that positively reg- 
ulates PLCY expression could at least partially enhance 
PLCY transcription in cells which are expressing detectable 
amounts of PLCY. 
4. Discussion 
PLC? is expressed in a tissue-specific manner, suggesting a 
special role of this enzyme within lymphoid cell function. 
Cloning and analysis of a 1.5 kb sequence 5’ of the first 
exon of human PLC? revealed a promoter lacking both, 
TATA- and CUT-boxes, with a stretch of highly GC-rich 
sequence motifs in its proximal part. A major RNA cap site 
was mapped by primer extension downstream of the GC-rich 
stretch with several consensus sites for the transcription factor 
SPl, including SPl sites, which partly overlapped the consen- 
sus sites for the GC factor, reported to repress transcriptional 
activation of the EGF receptor gene [22]. Proximal to that 
cluster, an AP2 site, previously described as responsive to 
CAMP and TPA [23,24], was located. The promoter proximal 
part conferred maximal activity in a transient transfection 
assay. In lesser quantity, extension products of a similar 
length to the major product were detected, indicating a less 
precise transcriptional activation mechanism similar to that 
previously reported for a TATA-box deleted SV40 early-pro- 
moter [28,29]. Deletion of the two GC-rich regions abrogated 
the activity of the PLCY promoter in transient transfection 
assays. This finding indicates that the Spl clusters may pos- 
sibly substitute for the missing TATA motif, which generally 
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confers basal transcriptional activation to most known core- 
promoters [30,31]. In accordance to previous reports [32,33], 
the cooperative binding of several Spl factors in combination 
with other factors might be neccessary for full transcriptional 
activity of the PLCY promoter. In case of the TATA-less 
promoter for human adenosine deaminase, deletion of the 
very proximal Spl site rendered the promoter inactive, while 
deletion of the more distal Spl motifs affected the transcrip- 
tion only modestly [31]. In case of the TATA-less promoter 
for the insulin-like growth factor binding protein-2 from rat 
[30], where Spl/GC-factor binding sites are located more dis- 
tant from the transcriptional start between positions -234 to 
-215 and from -189 to -125, deletion of these regions de- 
creased promoter activity 25-fold, although it did not, how- 
ever, render the remaining construct completely inactive. 
Thus, in addition to its compositional arrangement, the posi- 
tioning of these elements seems to have a significant impact on 
promoter activity. Deletion of a PLCY promoter sequence 
carrying an AP2 site at position -174, and in addition that 
of one located within the first, untranslated exon at position 
+73, leads to some decrease of promoter activation in four 
out of five transfected cell lines, and to a major drop in acti- 
vation in Raji cells. This suggests a major role for AP2 in 
Raji, whereas the effect of this motif could be minor in the 
four others. Deletion of a sequence carrying a serum response 
element (SRE) at position -567 also had a very moderate 
effect, except within the cell line BJA-B, where a more pro- 
nounced drop of activity could be seen. Thus, from the dele- 
tional analysis, the GC-rich region with its Spl and GC-factor 
motifs seems to be the most significant requirement for pro- 
moter function whereas other motifs, notably AP2 and SRE, 
seem to have a more moderately positive effect. The negative 
impact of a region between position -622 to -293 and nt -293 
to nt -198 was not specifically investigated. This stretch seems 
to repress activity in all tested cell lines, most dramatic in 
Raji. 
To our surprise, all promoter constructs showing activity in 
lymphoid cells did the same in adherent cell lines, where en- 
dogenous PLCJ expression cannot be detected, suggesting 
that the tissue specificity of PLCY might not be defined by 
its promoter sequence. On the other hand, the amplitude of its 
transcriptional activity may be regulated by interaction of a 
subset of rather ubiquitous transcription factors, such as Spl, 
GC factor, SRF, or factors binding to AP2 motifs that may 
be exogenously stimulated and regulated [2]. As these tran- 
scription factors are reported to be constitutively present, they 
may enhance transcription of PLCY only in those cells, where 
the transcriptional unit, and in particular, the promoter, is 
accessible for this type of transcriptional activation. 
The rat promoter for the ubiquitously expressed PLCy’ 
gene has been already isolated and characterized [34]. This 
promoter resembles that of PLCY. It lacks a TATA box, 
shows GC-rich sequence stretches and contains clusters of 
Spl and GC-factor binding sites as well as an AP2-binding 
motif. The similarity of these promoters suggests that tissue 
specificity of PLCY expression is determined by means other 
than the promoter sequence. The promoter of PLA2, a phos- 
pholipase involved in the production of lysophospholipids, 
prostaglandins and leukotrienes, [35] lacks a TATA box, but 
shows no further similarity to the PLCY promoter. 
As PLCY is suspected to be a signal transducer down- 
stream of the B-cell receptor complex, an increase of its 
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mRNA might be a stabilizing response to B-cell receptor-in- 
itiated signals which may finally lead to the clonal expansion 
of an antigen triggered B-cell. As the PLCY RNA is appar- 
ently quite stable compared to that of c-myc, the induction of 
RNA levels in BJA-B cells is likely to depend, at least in part, 
on the transcriptional activation of the gene. TPA and retinoic 
acid positively influence B-cell viability and differentiation, 
and could resemble inputs given to an antigen triggered B- 
cell in vivo. TPA and retinoic acid treatment in fact stimu- 
lated PLCY expression in the B-cell line BJA-B. The increase 
of PLCY mRNA in 5-azacytidine treated Raji cells might 
suggest the expression of this gene, especially when it is low 
or missing, to be directly or indirectly controlled by mechan- 
isms of DNA methylation. 
In summary, this study suggests a specific role for the tran- 
scription factor SPl and its corresponding binding motif on 
the transcriptional activation of the PLCf gene. As promoter 
fragments fused to a luc reporter gene give rise to transcrip- 
tion of the reporter in cell lines which do not express detect- 
able amounts endogenous of PLCY, one may suggest that, 
once the gene is accessible, a rather abundant set of transcrip- 
tion factors, most prominently SPl, mediates transcriptional 
activation. The causality of tissue-specific PLCg expression, 
however, must rather be searched for within mechanisms of 
expressional regulation, which are not neccessarily confined to 
cell-specific factor/promoter interaction. 
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